Details for New Drug Application (NDA): 201655
✉ Email this page to a colleague
The generic ingredient in OPANA ER is oxymorphone hydrochloride. There are nine drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the oxymorphone hydrochloride profile page.
Summary for 201655
Tradename: | OPANA ER |
Applicant: | Endo Pharms |
Ingredient: | oxymorphone hydrochloride |
Patents: | 4 |
Medical Subject Heading (MeSH) Categories for 201655
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 5MG | ||||
Approval Date: | Dec 9, 2011 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Try for Free | Patent Expiration: | Jul 10, 2029 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
Patent: | ⤷ Try for Free | Patent Expiration: | Sep 15, 2025 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Try for Free | Patent Expiration: | Jun 21, 2027 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE |
Expired US Patents for NDA 201655
Complete Access Available with Subscription